From the *Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, IN
the †Department of Pediatrics, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, IN
the ‡Department of Surgery, Division of Pediatric Surgery, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, IN
the §Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, IN.
Received February 17, 2022; accepted July 10, 2022.
Dr Molleston has relationships with Abbvie, Albireo, Mirum, and Gilead biopharmaceutical companies and the Cystic Fibrosis Foundation that do not affect this work. The remaining authors report no conflicts of interest.
This data was presented as a virtual abstract at the 2020 North American Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Annual Meeting on November 2, 2020.
Address correspondence and reprint requests to Paroma Bose, MD, Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Indiana University School of Medicine/Riley Hospital for Children, 705 Riley Hospital Dr. ROC 4210, Indianapolis, IN 46202 (e-mail: [email protected]).
